Gaming Press Releases

Wise.Guy.

Global Rheumatoid Arthritis Drugs and Companies Pipeline Review H2 2016

PUNE, INDIA, November 15, 2016 /EINPresswire.com/ — The report provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/575881-rheumatoid-arthritis-pipeline-review-h1-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis
– The report reviews pipeline therapeutics for Rheumatoid Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Rheumatoid Arthritis therapeutics and enlists all their major and minor projects
– The report assesses Rheumatoid Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis

Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
Introduction 12
Rheumatoid Arthritis Overview 13
Therapeutics Development 14
Rheumatoid Arthritis – Therapeutics under Development by Companies 16
Rheumatoid Arthritis – Therapeutics under Investigation by Universities/Institutes 34
Rheumatoid Arthritis – Pipeline Products Glance 37
Rheumatoid Arthritis – Products under Development by Companies 41
Rheumatoid Arthritis – Products under Investigation by Universities/Institutes 69
Rheumatoid Arthritis – Companies Involved in Therapeutics Development 72
Rheumatoid Arthritis – Therapeutics Assessment 294
Drug Profiles 328
Rheumatoid Arthritis – Dormant Projects 1016
Rheumatoid Arthritis – Discontinued Products 1064
Rheumatoid Arthritis – Product Development Milestones 1075

Access Report @ https://www.wiseguyreports.com/reports/575881-rheumatoid-arthritis-pipeline-review-h1-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: PR

Wise.Guy.

PUNE, INDIA, November 15, 2016 /EINPresswire.com/ —

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/742659-global-unmanned-aerial-vehicle-system-market-research-report-2016

This report studies Unmanned Aerial Vehicle System in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
Boeing
PARROT
3DR
Titan Aerospace
AAI
Northrop Grumman
IAI
Dynali helicopters
BAE System
SAGEM

Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Unmanned Aerial Vehicle System in these regions, from 2011 to 2021 (forecast), like
North America
Europe
China
Japan
Southeast Asia
India

Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into
Fixed-wing UAV
Rotary wing UAV
Flapping-wing UAV
Airship type UAV

Split by application, this report focuses on consumption, market share and growth rate of Unmanned Aerial Vehicle System in each application, can be divided into
Military UAV
Civilian UAV
Application 3

Complete Report Details @ https://www.wiseguyreports.com/reports/742659-global-unmanned-aerial-vehicle-system-market-research-report-2016

Table of Contents

Global Unmanned Aerial Vehicle System Market Research Report 2016

1 Unmanned Aerial Vehicle System Market Overview
1.1 Product Overview and Scope of Unmanned Aerial Vehicle System
1.2 Unmanned Aerial Vehicle System Segment by Type
1.2.1 Global Production Market Share of Unmanned Aerial Vehicle System by Type in 2015
1.2.2 Fixed-wing UAV
1.2.3 Rotary wing UAV
1.2.4 Flapping-wing UAV
1.2.5 Airship type UAV
1.3 Unmanned Aerial Vehicle System Segment by Application
1.3.1 Unmanned Aerial Vehicle System Consumption Market Share by Application in 2015
1.3.2 Military UAV
1.3.3 Civilian UAV
1.3.4 Application 3
1.4 Unmanned Aerial Vehicle System Market by Region
1.4.1 North America Status and Prospect (2011-2021)
1.4.2 Europe Status and Prospect (2011-2021)
1.4.3 China Status and Prospect (2011-2021)
1.4.4 Japan Status and Prospect (2011-2021)
1.4.5 Southeast Asia Status and Prospect (2011-2021)
1.4.6 India Status and Prospect (2011-2021)
1.5 Global Market Size (Value) of Unmanned Aerial Vehicle System (2011-2021)

2 Global Unmanned Aerial Vehicle System Market Competition by Manufacturers
2.1 Global Unmanned Aerial Vehicle System Production and Share by Manufacturers (2015 and 2016)
2.2 Global Unmanned Aerial Vehicle System Revenue and Share by Manufacturers (2015 and 2016)
2.3 Global Unmanned Aerial Vehicle System Average Price by Manufacturers (2015 and 2016)
2.4 Manufacturers Unmanned Aerial Vehicle System Manufacturing Base Distribution, Sales Area and Product Type
2.5 Unmanned Aerial Vehicle System Market Competitive Situation and Trends
2.5.1 Unmanned Aerial Vehicle System Market Concentration Rate
2.5.2 Unmanned Aerial Vehicle System Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Unmanned Aerial Vehicle System Production, Revenue (Value) by Region (2011-2016)
3.1 Global Unmanned Aerial Vehicle System Production by Region (2011-2016)
3.2 Global Unmanned Aerial Vehicle System Production Market Share by Region (2011-2016)
3.3 Global Unmanned Aerial Vehicle System Revenue (Value) and Market Share by Region (2011-2016)
3.4 Global Unmanned Aerial Vehicle System Production, Revenue, Price and Gross Margin (2011-2016)
3.5 North America Unmanned Aerial Vehicle System Production, Revenue, Price and Gross Margin (2011-2016)
3.6 Europe Unmanned Aerial Vehicle System Production, Revenue, Price and Gross Margin (2011-2016)
3.7 China Unmanned Aerial Vehicle System Production, Revenue, Price and Gross Margin (2011-2016)
3.8 Japan Unmanned Aerial Vehicle System Production, Revenue, Price and Gross Margin (2011-2016)
3.9 Southeast Asia Unmanned Aerial Vehicle System Production, Revenue, Price and Gross Margin (2011-2016)
3.10 India Unmanned Aerial Vehicle System Production, Revenue, Price and Gross Margin (2011-2016)

4 Global Unmanned Aerial Vehicle System Supply (Production), Consumption, Export, Import by Regions (2011-2016)
4.1 Global Unmanned Aerial Vehicle System Consumption by Regions (2011-2016)
4.2 North America Unmanned Aerial Vehicle System Production, Consumption, Export, Import by Regions (2011-2016)
4.3 Europe Unmanned Aerial Vehicle System Production, Consumption, Export, Import by Regions (2011-2016)
4.4 China Unmanned Aerial Vehicle System Production, Consumption, Export, Import by Regions (2011-2016)
4.5 Japan Unmanned Aerial Vehicle System Production, Consumption, Export, Import by Regions (2011-2016)
4.6 Southeast Asia Unmanned Aerial Vehicle System Production, Consumption, Export, Import by Regions (2011-2016)
4.7 India Unmanned Aerial Vehicle System Production, Consumption, Export, Import by Regions (2011-2016)

……….

7 Global Unmanned Aerial Vehicle System Manufacturers Profiles/Analysis
7.1 Boeing
7.1.1 Company Basic Information, Manufacturing Base and Its Competitors
7.1.2 Unmanned Aerial Vehicle System Product Type, Application and Specification
7.1.2.1 Type I
7.1.2.2 Type II
7.1.3 Boeing Unmanned Aerial Vehicle System Production, Revenue, Price and Gross Margin (2015 and 2016)
7.1.4 Main Business/Business Overview
7.2 PARROT
7.2.1 Company Basic Information, Manufacturing Base and Its Competitors
7.2.2 Unmanned Aerial Vehicle System Product Type, Application and Specification
7.2.2.1 Type I
7.2.2.2 Type II
7.2.3 PARROT Unmanned Aerial Vehicle System Production, Revenue, Price and Gross Margin (2015 and 2016)
7.2.4 Main Business/Business Overview
7.3 3DR
7.3.1 Company Basic Information, Manufacturing Base and Its Competitors
7.3.2 Unmanned Aerial Vehicle System Product Type, Application and Specification
7.3.2.1 Type I
7.3.2.2 Type II
7.3.3 3DR Unmanned Aerial Vehicle System Production, Revenue, Price and Gross Margin (2015 and 2016)
7.3.4 Main Business/Business Overview
7.4 Titan Aerospace
7.4.1 Company Basic Information, Manufacturing Base and Its Competitors
7.4.2 Unmanned Aerial Vehicle System Product Type, Application and Specification
7.4.2.1 Type I
7.4.2.2 Type II

…..Continued

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=742659

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: PR

Wise.Guy.

Osteoarthritis Pain Therapeutic Pipeline Market Review, H2 2016

PUNE, INDIA, November 8, 2016 /EINPresswire.com/ — Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. This further leads to rubbing of the bones against each other stimulating pain. The predisposing factors are age, joint injury, obesity and heredity. It may be diagnosed by physical examination and MRI and X-ray imaging. The condition may be controlled by weight control, exercise and medication.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/731573-osteoarthritis-pain-pipeline-review-h2-2016

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 19, 6, 1, 17, 5 and 1 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively for Osteoarthritis Pain.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
Introduction 6
Osteoarthritis Pain Overview 7
Therapeutics Development 8
Osteoarthritis Pain – Therapeutics under Development by Companies 10
Osteoarthritis Pain – Therapeutics under Investigation by Universities/Institutes 13
Osteoarthritis Pain – Pipeline Products Glance 14
Osteoarthritis Pain – Products under Development by Companies 18
Osteoarthritis Pain – Products under Investigation by Universities/Institutes 22
Osteoarthritis Pain – Companies Involved in Therapeutics Development 23
Osteoarthritis Pain – Therapeutics Assessment 62
Drug Profiles 77
Osteoarthritis Pain – Dormant Projects 187
Osteoarthritis Pain – Discontinued Products 192
Osteoarthritis Pain – Product Development Milestones 194

Access Report @ https://www.wiseguyreports.com/reports/731573-osteoarthritis-pain-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: PR

Wise.Guy.

Global Graft Versus Host Disease (GVHD) Drugs and Companies Pipeline Review H2 2016

PUNE, INDIA, November 15, 2016 /EINPresswire.com/ —
The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/685908-graft-versus-host-disease-gvhd-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)
– The report reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Graft Versus Host Disease (GVHD) therapeutics and enlists all their major and minor projects
– The report assesses Graft Versus Host Disease (GVHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD)

Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Graft Versus Host Disease (GVHD) Overview 11
Therapeutics Development 12
Pipeline Products for Graft Versus Host Disease (GVHD) – Overview 12
Pipeline Products for Graft Versus Host Disease (GVHD) – Comparative Analysis 13
Graft Versus Host Disease (GVHD) – Therapeutics under Development by Companies 14
Graft Versus Host Disease (GVHD) – Therapeutics under Investigation by Universities/Institutes 19
Graft Versus Host Disease (GVHD) – Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Graft Versus Host Disease (GVHD) – Products under Development by Companies 25
Graft Versus Host Disease (GVHD) – Products under Investigation by Universities/Institutes 30
Graft Versus Host Disease (GVHD) – Companies Involved in Therapeutics Development 31
AbbVie Inc 31
AbGenomics International, Inc. 32
Actelion Ltd 33
Alexion Pharmaceuticals Inc 34
Amunix Operating Inc. 35
Apceth GmbH & Co. KG 36
arGEN-X BV 37
Athersys, Inc. 38
Bellicum Pharmaceuticals, Inc. 39
Bio-Cancer Treatment International Limited 40
Biogen Inc 41
Bristol-Myers Squibb Company 42
Cantex Pharmaceuticals, Inc. 43
Capricor Therapeutics, Inc. 44
Cell2B S.A. 45
CellECT Bio, Inc. 46
Cynata Therapeutics Limited 47
Cytodyn Inc. 48
Dompe Farmaceutici S.p.A. 49
Dr. Falk Pharma GmbH 50
Escape Therapeutics, Inc. 51
F. Hoffmann-La Roche Ltd. 52
Fate Therapeutics, Inc. 53
Generon (Shanghai) Corporation Ltd. 54
Gilead Sciences, Inc. 55
GlaxoSmithKline Plc 56
Idera Pharmaceuticals, Inc. 57
ImmuNext, Inc. 58
Immunomedics, Inc. 59

Access Report @ https://www.wiseguyreports.com/reports/685908-graft-versus-host-disease-gvhd-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: PR

Wise.Guy.

Lassa Fever Treatment Pipeline Review H2 2016

PUNE, INDIA, November 15, 2016 /EINPresswire.com/ — The report provides comprehensive information on the therapeutics under development for Lassa Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lassa Fever and features dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/543765-lassa-fever-pipeline-review-h1-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the global therapeutic landscape of Lassa Fever
– The report reviews pipeline therapeutics for Lassa Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Lassa Fever therapeutics and enlists all their major and minor projects
– The report assesses Lassa Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Lassa Fever

Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Lassa Fever
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Lassa Fever pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Lassa Fever Overview 7
Therapeutics Development 8
Pipeline Products for Lassa Fever – Overview 8
Pipeline Products for Lassa Fever – Comparative Analysis 9
Lassa Fever – Therapeutics under Development by Companies 10
Lassa Fever – Therapeutics under Investigation by Universities/Institutes 11
Lassa Fever – Pipeline Products Glance 12
Early Stage Products 12
Lassa Fever – Products under Development by Companies 13
Lassa Fever – Products under Investigation by Universities/Institutes 14
Lassa Fever – Companies Involved in Therapeutics Development 15
Arno Therapeutics, Inc. 15
Celgene Corporation 16
Etubics Corporation 17
Kineta, Inc. 18
Profectus BioSciences, Inc. 19
SIGA Technologies, Inc. 20
Lassa Fever – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
AR-12 – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
CC-11050 – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
DEF-201 – Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
FBH-003 – Drug Profile 36

Access Report @ https://www.wiseguyreports.com/reports/543765-lassa-fever-pipeline-review-h1-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: PR

Wise.Guy.

Dyskinesia Treatment Pipeline Review H2 2016

PUNE, INDIA, November 15, 2016 /EINPresswire.com/ — The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/685895-dyskinesia-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the global therapeutic landscape of Dyskinesia
– The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects
– The report assesses Dyskinesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Dyskinesia

Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Dyskinesia
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Dyskinesia Overview 8
Therapeutics Development 9
Pipeline Products for Dyskinesia – Overview 9
Pipeline Products for Dyskinesia – Comparative Analysis 10
Dyskinesia – Therapeutics under Development by Companies 11
Dyskinesia – Therapeutics under Investigation by Universities/Institutes 14
Dyskinesia – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Dyskinesia – Products under Development by Companies 18
Dyskinesia – Products under Investigation by Universities/Institutes 21
Dyskinesia – Companies Involved in Therapeutics Development 22
Adamas Pharmaceuticals, Inc. 22
Addex Therapeutics Ltd 23
Advicenne 24
Astraea Therapeutics, LLC 25
Bionomics Limited 26
Catalyst Biosciences, Inc. 27
Catalyst Pharmaceuticals, Inc. 28
Clevexel Pharma SAS 29
Contera Pharma ApS 30
EpiVax, Inc. 31
Heptares Therapeutics Limited 32
Hua Medicine (Shanghai) Ltd. 33
Integrative Research Laboratories Sweden AB 34
Ipsen S.A. 35
Merz Pharma GmbH & Co. KgaA 36
MitoDys Therapeutics Limited 37
Neurim Pharmaceuticals Ltd 38
Neurocrine Biosciences, Inc. 39
Neurolixis Inc. 40
Osmotica Pharmaceutical Corp. 41
Otsuka Holdings Co., Ltd. 42
Phenomenome Discoveries, Inc. 43
Revance Therapeutics, Inc. 44
Sage Therapeutics, Inc. 45
SciFluor Life Sciences, LLC 46
SOM Innovation Biotech SL 47
Synchroneuron Inc. 48
Teva Pharmaceutical Industries Ltd. 49
Dyskinesia – Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 55
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
(dextromethorphan + quinidine sulfate) – Drug Profile 62
A2M-13677 – Drug Profile 67
abobotulinumtoxin A – Drug Profile 68
acamprosate calcium SR – Drug Profile 72

Access Report @ https://www.wiseguyreports.com/reports/685895-dyskinesia-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: PR

Wise.Guy.

Global Secondary Progressive Multiple Sclerosis (SPMS) Drugs and Companies Pipeline Review H2 2016

PUNE, INDIA, November 15, 2016 /EINPresswire.com/ — The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and features dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/619266-secondary-progressive-multiple-sclerosis-spms-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the global therapeutic landscape of Secondary Progressive Multiple Sclerosis (SPMS)
– The report reviews pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Secondary Progressive Multiple Sclerosis (SPMS) therapeutics and enlists all their major and minor projects
– The report assesses Secondary Progressive Multiple Sclerosis (SPMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS)

Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS)
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Secondary Progressive Multiple Sclerosis (SPMS) Overview 9
Therapeutics Development 10
Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) – Overview 10
Secondary Progressive Multiple Sclerosis (SPMS) – Therapeutics under Development by Companies 11
Secondary Progressive Multiple Sclerosis (SPMS) – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Secondary Progressive Multiple Sclerosis (SPMS) – Products under Development by Companies 16
Secondary Progressive Multiple Sclerosis (SPMS) – Companies Involved in Therapeutics Development 17
AB Science SA 17
Actelion Ltd 18
Biogen, Inc. 19
F. Hoffmann-La Roche Ltd. 20
Genzyme Corporation 21
Glialogix, Inc. 22
Immune Response BioPharma, Inc. 23
Innate Immunotherapeutics Ltd 24
Kyorin Pharmaceutical Co., Ltd. 25
Mallinckrodt Plc 26
MedDay SA 27
MedImmune, LLC 28
Merck KGaA 29
Meta-IQ ApS 30
Novartis AG 31
Opexa Therapeutics, Inc. 32
Xenetic Biosciences (UK) Limited 33
Secondary Progressive Multiple Sclerosis (SPMS) – Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 38
7Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
biotin – Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
DC-TAB – Drug Profile 49
Product Description 49

Access Report @ https://www.wiseguyreports.com/reports/619266-secondary-progressive-multiple-sclerosis-spms-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: PR